Multistep, effective drug distribution within solid tumors

The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a miniature drug source offers an alternative to both systemic delivery and intratumoral injection. Presented here is a model of drug distribution from such a source, in a multistep process. At delivery onset the drug mainly affects the closest surroundings. Such ‘priming’ enables drug penetration to successive cell layers. Tumor ‘void volume’ (volume not occupied by cells) increases, facilitating lymphatic perfusion. The drug is then transported by hydraulic convection downstream along interstitial fluid pressure (IFP) gradients, away from the tumor core. After a week tumor cell death occurs throughout the entire tumor and IFP gradients are flattened. Then, the drug is transported mainly by ‘mixing’, powered by physiological bulk body movements. Steady state is achieved and the drug covers the entire tumor over several months. Supporting measurements are provided from the LODER™ system, releasing siRNA against mutated KRAS over months in pancreatic cancer in-vivo models. LODER™ was also successfully employed in a recent Phase 1/2 clinical trial with pancreatic cancer patients.

[1]  R. K. Jain,et al.  Intratumoral infusion of fluid: estimation of hydraulic conductivity and implications for the delivery of therapeutic agents. , 1998, British Journal of Cancer.

[2]  I. Tannock,et al.  The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. , 2006, Cancer research.

[3]  A. Jimeno,et al.  Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. , 2015, Drugs of today.

[4]  Kaamran Raahemifar,et al.  Effect of tumor shape, size, and tissue transport properties on drug delivery to solid tumors , 2014, Journal of biological engineering.

[5]  Rodolfo Repetto,et al.  Mixing processes in the vitreous chamber induced by eye rotations. , 2010, Physics in medicine and biology.

[6]  R K Jain,et al.  Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[7]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[8]  M. Lerch,et al.  A Syngeneic Orthotopic Murine Model of Pancreatic Adenocarcinoma in the C57/BL6 Mouse Using the Panc02 and 6606PDA Cell Lines , 2011, European Surgical Research.

[9]  Paul M. Mathias,et al.  Extension of the Peng-Robinson equation of state to complex mixtures: Evaluation of the various forms of the local composition concept , 1983 .

[10]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[11]  R. Eliakim,et al.  RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients , 2015, Oncotarget.

[12]  D. Morin,et al.  Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection. , 2009, Current medicinal chemistry.

[13]  O. Gofrit,et al.  Intratumoral delivery of paclitaxel for treatment of orthotopic prostate cancer. , 2009, Journal of pharmaceutical sciences.

[14]  D. Scadden,et al.  Active movement of T cells away from a chemokine , 2000, Nature Medicine.

[15]  Xue-mei Ma,et al.  Identification of Suitable Reference Genes for qPCR Analysis of Serum microRNA in Gastric Cancer Patients , 2012, Digestive Diseases and Sciences.

[16]  Bin Chen,et al.  Predictive Models of Diffusive Nanoparticle Transport in 3-Dimensional Tumor Cell Spheroids , 2013, The AAPS Journal.

[17]  G. Sczakiel,et al.  Selected Strategies for the Delivery of siRNA In Vitro and In Vivo , 2010 .

[18]  Lei Xu,et al.  Pancreas Microenvironment Promotes VEGF Expression and Tumor Growth: Novel Window Models for Pancreatic Tumor Angiogenesis and Microcirculation , 2001, Laboratory Investigation.

[19]  Paolo A Ascierto,et al.  Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types , 2013, Clinical Cancer Research.

[20]  S. Soefje,et al.  Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[21]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Wahid Khan,et al.  Focal Controlled Drug Delivery , 2014, Advances in Delivery Science and Technology.

[23]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[24]  Judy Lucas,et al.  Ammonia Derived from Glutaminolysis Is a Diffusible Regulator of Autophagy , 2010, Science Signaling.

[25]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[26]  D. Kamei,et al.  Modeling Mass Transfer from Carmustine-Loaded Polymeric Implants for Malignant Gliomas , 2014, Journal of laboratory automation.

[27]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[28]  R. Jain,et al.  Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy , 2012, Proceedings of the National Academy of Sciences.

[29]  S. Bergqvist,et al.  Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity , 2012, Cancer Immunology, Immunotherapy.

[30]  M. Jacobson,et al.  A comparative Brownian dynamics investigation between small linear and circular DNA: Scaling of diffusion coefficient with size and topology of DNA , 2014 .

[31]  Rakesh K. Jain,et al.  Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels , 2013, Nature Communications.

[32]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[33]  S. Kawakami,et al.  Pressure-mediated transfection of murine spleen and liver. , 2009, Human gene therapy.

[34]  M. Swartz,et al.  Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity , 2012, Nature Reviews Cancer.

[35]  Stanley T. Crooke,et al.  Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells , 2007, Nucleic acids research.

[36]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[37]  D. Haussecker.  Current issues of RNAi therapeutics delivery and development. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[38]  Saroja Ramanujan,et al.  Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. , 2002, Biophysical journal.

[39]  H. Salvesen,et al.  A New Method for Isolation of Interstitial Fluid from Human Solid Tumors Applied to Proteomic Analysis of Ovarian Carcinoma Tissue , 2011, PloS one.

[40]  R K Jain,et al.  Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.

[41]  K. Behrns.  FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .

[42]  Abraham J Domb,et al.  Polyanhydrides: an overview. , 2002, Advanced drug delivery reviews.

[43]  S. Kaushal,et al.  Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. , 2013, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[44]  Y. Kopelman,et al.  Mutant KRAS is a druggable target for pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[45]  N. Ben-Dov,et al.  Enhancement of Cell Membrane Invaginations, Vesiculation and Uptake of Macromolecules by Protonation of the Cell Surface , 2012, PloS one.

[46]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[47]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[48]  Triantafyllos Stylianopoulos,et al.  Combining two strategies to improve perfusion and drug delivery in solid tumors , 2013, Proceedings of the National Academy of Sciences.

[49]  A. Enk,et al.  Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma , 2015, PloS one.

[50]  Heiko Rieger,et al.  Interstitial Fluid Flow and Drug Delivery in Vascularized Tumors: A Computational Model , 2013, PloS one.

[51]  X. Xu,et al.  Towards an integrated systems-based modelling framework for drug transport and its effect on tumour cells , 2014, Journal of biological engineering.

[52]  Charles M Perou,et al.  Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models , 2014, Clinical Cancer Research.

[53]  Manfred Westphal,et al.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.

[54]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.